Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

257
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

756
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
756
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

490
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
490
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.3K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

354
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
354

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL15-mediated crosstalk between LSECs and CD8⁺ tissue-resident memory T cells drives alcohol-associated hepatitis.

Hepatology communications·2026
Same author

Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients with Severe Alcohol-associated Hepatitis.

Clinical and translational gastroenterology·2026
Same author

A lifecycle governance and learning health system framework for trustworthy, generalizable, and sustainable human-ai partnership in clinical practice: Lessons from the asthma-guidance and prediction system (A-GPS).

Journal of the National Medical Association·2026
Same author

SIRPα Cleavage Is Associated with Inflammatory Response, Corticosteroid Nonresponse, and Worse Prognosis in Clinical and Preclinical Models of Alcohol-Associated Hepatitis.

The American journal of pathology·2026
Same author

Clinician engagement shapes the impact of AI-based ECG screening for chronic liver disease in primary care.

NPJ digital medicine·2026
Same author

Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study.

Hepatology (Baltimore, Md.)·2026
Same journal

Genetic and Genomic Insights Across the SLD Spectrum.

Clinical and molecular hepatology·2026
Same journal

Comparison of Clinical Practice Guidelines for Chronic Hepatitis B: Natural History Classification and Treatment Initiation.

Clinical and molecular hepatology·2026
Same journal

Clinical utility of liquid biopsy in biliary tract cancer: Diagnosis to treatment monitoring.

Clinical and molecular hepatology·2026
Same journal

Transitions from Combustible to Noncombustible Tobacco Use and Liver Outcomes in Steatotic Liver Disease.

Clinical and molecular hepatology·2026
Same journal

Chronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challenges.

Clinical and molecular hepatology·2026
Same journal

NAT10 deficiency in aging drives impaired liver regeneration by disrupting PARP10 in an ac4C-dependent manner.

Clinical and molecular hepatology·2026
See all related articles

Related Experiment Video

Updated: Mar 30, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

15.4K

Managing alcoholic liver disease.

Vijay H Shah1

  • 1Gastroenterology Research Unit, Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Clinical and Molecular Hepatology
|November 3, 2015
PubMed
Summary
This summary is machine-generated.

Alcoholic liver disease is a major global health issue. While supportive care and abstinence are crucial, new pharmacotherapies are under investigation for this severe condition.

Keywords:
AlcoholAlcoholic hepatitisCorticosteroidsLiver transplantation

More Related Videos

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

509
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.6K

Related Experiment Videos

Last Updated: Mar 30, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

15.4K
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

509
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.6K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Alcoholic liver disease (ALD) is a leading cause of liver morbidity and mortality worldwide.
  • Current diagnostic and prognostic models exist, but the role of liver biopsy, especially in alcoholic hepatitis, requires further clarification.
  • Despite numerous treatment trials, optimal pharmacotherapy for ALD remains elusive.

Purpose of the Study:

  • To review the current landscape of alcoholic liver disease management.
  • To highlight the importance of supportive care, abstinence, and nutrition.
  • To discuss emerging treatment strategies undergoing evaluation.

Main Methods:

  • Review of existing literature and clinical trial data on alcoholic liver disease.
  • Analysis of diagnostic and prognostic models.
  • Evaluation of current and investigational pharmacotherapy approaches.

Main Results:

  • Supportive care, abstinence, and nutritional support are fundamental to ALD management.
  • The precise role of liver biopsy in specific ALD contexts, such as alcoholic hepatitis, needs further definition.
  • Several novel pharmacotherapeutic agents are in development and undergoing rigorous evaluation.

Conclusions:

  • Alcoholic liver disease necessitates comprehensive management strategies focusing on abstinence and supportive care.
  • Ongoing research and clinical trials are crucial for developing effective pharmacotherapy options.
  • Future treatments hold promise for improving outcomes in patients with severe alcoholic liver disease.